Correlation between cerebral blood volume measurements by perfusion-weighted magnetic resonance imaging and two-year progression-free survival in gliomas

Neuroradiology Journal

Volumn 26, Issue 4, 2013, Pages 385-395

  Spampinato, Maria Vittoria ^a   Schiarelli, C ^b   Cianfoni, A ^a   Giglio, P ^a   Welsh, C T ^a   Bisdas, S ^c   Rumboldt, Z ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Brain tumors; Glioma; MR imaging; MR perfusion; Progression free survival

Indexed keywords

TEMOZOLOMIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTOMA; BLOOD VOLUME; CANCER SURVIVAL; CEREBRAL BLOOD VOLUME; CLINICAL ARTICLE; DRUG MEGADOSE; FEMALE; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOTHESIS; MALE; MULTIPLE CYCLE TREATMENT; OLIGODENDROGLIOMA; PERFUSION WEIGHTED IMAGING; PROGRESSION FREE SURVIVAL; RECEIVER OPERATING CHARACTERISTIC; SURVIVAL PREDICTION;

EID: 84884720705     PISSN: 19714009     EISSN: None     Source Type: Journal    
DOI: 10.1177/197140091302600404     Document Type: Article

References (33)

1. Mineo JF, Bordron A, Baroncini M, et al. Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma. J Neurooncol. 2007; 85 (3): 281-287. (Pubitemid 350142517)
2. Devaux BC, O'Fallon JR, Kelly PJ. Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg. 1993; 78 (5): 767-775. (Pubitemid 23121919)
3. Stark AM, Nabavi A, Mehdorn HM et al. Glioblastoma multiforme-report of 267 cases treated at a single institution. Surg Neurol. 2005; 63 (2): 162-169; discussion 169.
4. Maia AC Jr., Malheiros SM, da Rocha AJ, et al, MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. Am J Neuroradiol. 2005; 26 (4): 777-783. (Pubitemid 43079767)
5. Basu S, Alavi A. Molecular imaging (PET) of brain tumors. Neuroimaging Clin N Am. 2009; 19 (4): 625-646.
6. Kong DS, Song SY, Kim DH, et al. Prognostic significance of c-Met expression in glioblastomas. Cancer. 2009; 115 (1): 140-148.
7. Price SJ. Advances in imaging low-grade gliomas. Adv Tech Stand Neurosurg. 2010; 35: 1-34.
8. Okamoto Y, Di Patre PL, Burkhard C, et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol. 2004; 108 (1): 49-56. (Pubitemid 38961073)
9. Piepmeier J, Christopher S, Spencer D, et al. Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas. Neurosurgery. 1996; 38: 872-878; discussion 878-879.
10. Arvinda HR, Kesavadas C, Sarma PS, et al. Glioma grading: sensitivity, specificity, positive and negative predictive values of diffusion and perfusion imaging. J Neurooncol. 2009; 94: 87-96.
11. Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro Oncol. 2003; 3 (3): 193-200.
12. Sugahara T, Korogi Y, Kochi M, et al. Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. Am J Roentgenol. 1998; 171 (6): 1479-1486. (Pubitemid 28531609)
13. Rosen BR, Belliveau JW, Vevea JM, et al. Perfusion imaging with NMR contrast agents. Magn Reson Med. 1990; 14 (2): 249-265. (Pubitemid 20248610)
14. Law M, Oh S, Babb JS, et al. Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging-prediction of patient clinical response. Radiology. 2006; 238: 658-667. (Pubitemid 43134379)
15. Danchaivijitr N, Waldman AD, Tozer DJ, et al. Lowgrade gliomas: do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation? Radiology. 2008; 247 (1): 170-178.
16. Chaskis C, Stadnik T, Michotte A, et al. J. Prognostic value of perfusion-weighted imaging in brain glioma: a prospective study. Acta Neurochir (Wien). 2006; 148 (3): 277-285; discussion 285.
17. Daumas-Duport C, Scheithauer B, O'Fallon J, et al. Grading of astrocytomas. A simple and reproducible method. Cancer. 1988; 62 (10): 2152-2165. (Pubitemid 18261854)
18. Bisdas S, Kirkpatrick M, Giglio P, et al. Cerebral blood volume measurements by perfusion-weighted MR imaging in gliomas: ready for prime time in predicting short-term outcome and recurrent disease? Am J Neuroradiol. 2009; 30 (4): 681-688.
19. Hirai T, Murakami R, Nakamura H, et al. Prognostic value of perfusion MR imaging of high-grade astrocytomas: long-term follow-up study. Am J Neuroradiol. 2008; 29: 1505-1510.
20. Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology. 2008; 247 (2): 490-498.
21. Lev MH, Ozsunar Y, Henson JW, et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. Am J Neuroradiol. 2004; 25: 214-221. (Pubitemid 38235298)
22. Mills SJ, Patankar TA, Haroon HA, et al. Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma? Am J Neuroradiol. 2006; 27 (4): 853-858. (Pubitemid 44897736)
23. Caseiras GB, Chheang S, Babb J, et al. Relative cerebral blood volume measurements of low-grade gliomas predict patient outcome in a multi-institution setting. Eur J Radiol. 2012; 73 (2): 215-220.
24. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114 (2): 97-109. (Pubitemid 47103521)
25. Brem SS, Bierman PJ, Black P, et al. Central nervous system cancers. J Natl Compr Canc Netw. 2008; 6 (5): 456-504.
26. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352 (10): 987-996. (Pubitemid 40349501)
27. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010; 28 (11): 1963-1972.
28. Wetzel SG, Cha S, Johnson G, et al. Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology. 2002; 224 (3): 797-803. (Pubitemid 34919816)
29. Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002; 20 (8): 2076-2084. (Pubitemid 34408798)
30. Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. Am J Neuroradiol. 2003; 24 (10): 1989-1998. (Pubitemid 37444849)
31. Krex D, Klink B, Hartmann C, et al. Long-term survival with glioblastoma multiforme. Brain. 2007; 130 (Pt 10):: 2596-2606. (Pubitemid 47511715)
32. Whitmore RG, Krejza J, Kapoor GS, et al. Prediction of oligodendroglial tumor subtype and grade using perfusion weighted magnetic resonance imaging. J Neurosurg. 2007; 107 (3): 600-609. (Pubitemid 47451045)
33. Jenkinson MD, Smith TS, Joyce KA, et al. Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours. Neuroradiology. 2006; 48 (10): 703-713. (Pubitemid 44490047)